Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.

Arangalage, Dimitri; Degrauwe, Nils; Michielin, Olivier; Monney, Pierre; Özdemir, Berna C. (2021). Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. Cancer treatment reviews, 100, p. 102282. Elsevier 10.1016/j.ctrv.2021.102282

[img]
Preview
Text
1-s2.0-S0305737221001304-main.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (1MB) | Preview

Immune checkpoint inhibitors (ICIs) and BRAF and MEK inhibitors (BRAFi/MEKi) have drastically improved the outcome of melanoma patients. ICIs can induce myocarditis, a rare immune related adverse event (irAE) with an estimated lethality of 50%. BRAFi/MEKi may induce left ventricular ejection fraction decrease, hypertension or QT interval prolongation. While the BRAFi/MEKi induced cardiotoxicity is often reversible upon treatment discontinuation or dose adaptation and symptomatic therapy is often sufficient to restore cardiac function, the treatment of ICI-induced myocarditis mainly relies on high dose corticosteroids. There is no established therapy for steroid resistant myocarditis, yet various drugs have been reported to improve outcome. Shared epitopes between melanoma cells and cardiac tissue are thought to underlie the development of ICIs induced myocarditis. The mechanism of BRAFi/MEKi induced cardiotoxicity appears to be related to the Ras-Raf-MEK-ERK pathway in cardiomyocyte repair, survival and proliferation. With the emerging application of ICI-BRAFi/MEKi combinations, so called triplet therapies, differentiating between these two types of cardiotoxicity will become important for appropriate patient management. In this article we provide a summary of the existing literature on the pathophysiology, diagnosis and management of cardiotoxicity of melanoma therapies.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Özdemir, Berna

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1532-1967

Publisher:

Elsevier

Language:

English

Submitter:

Rebeka Gerber

Date Deposited:

23 Nov 2021 14:22

Last Modified:

05 Dec 2022 15:54

Publisher DOI:

10.1016/j.ctrv.2021.102282

PubMed ID:

34438238

Uncontrolled Keywords:

BRAF inhibitor Cardiotoxicity Heart failure Hypertension Immune checkpoint inhibitors Immune related adverse events MEK inhibitor Melanoma Myocarditis Pathophysiology

BORIS DOI:

10.48350/160862

URI:

https://boris.unibe.ch/id/eprint/160862

Actions (login required)

Edit item Edit item
Provide Feedback